SOST and bone fracture: By contrast, the ARCH study, which evaluates the comparison between Romosozumab (a monoclonal antibody which inhibits sclerostin) and Alendronate in the prevention of bone fractures in women with osteoporosis, although showing a higher and faster gain in bone mass and a reduction in hip fractures, observed a higher prevalence of cardiovascular events (2.5% vs. 1.9%).